sur Cambridge Isotope Laboratories, Inc.
Cambridge Isotope Laboratories, Inc. Expands 13C Production Capacity With North Star Project
Cambridge Isotope Laboratories, Inc. (CIL), the global leader in 13C and 13C urea production, has announced the startup of its North Star project. This initiative significantly expands the company’s production capabilities.
The North Star project, which began in mid-2020, is the world's largest 13C production cascade. Phase one concluded in March 2024, and production has been promising, with the first highly enriched 13C product expected in October 2024. Full-scale production is anticipated by April 2025.
According to CEO Cliff Caldwell, this is CIL's fourth 13C production system since 1990. Each system has incorporated the team's extensive experience, demonstrating significant benefits for CIL and its customers.
Mike Steiger, VP of Engineering and Project Execution, emphasized the importance of 13C products in various applications, including environmental testing and medical diagnostics. Notably, 13C urea is crucial for detecting H-pylori infections.
CIL maintains its position as the top producer of 13C isotopes, ensuring reliable capacity to support the commercialization of research.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Cambridge Isotope Laboratories, Inc.